Related Experiment Videos
Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection
Abstract:
The incidence of methicillin-resistant staphylococcal infections, for which vancomycin hydrochloride remains the only active cell-wall antibiotic therapy, is rising. Some physicians have been combining other antibiotics with vancomycin in hopes of obtaining a more effective regimen for the therapy of these infections. Rifampin has been advocated as a concurrent second antibiotic because of its extraordinary potent bactericidal activity for Staphylococcus aureus. When rifampin is used in combination with a cell-wall antibiotic, suppression of the development of rifampin resistance has been thought possible. We report a case of infection caused by a methicillin-resistant S aureus in which the rifampin resistance occurred during therapy with vancomycin and rifampin. The rifampin resistance was stable and was present after ten serial broth and agar passages. Physicians are cautioned against the indiscriminant or routine use of rifampin as a second antibiotic in combination with vancomycin for the therapy of infections caused by S aureus.
Insights
Physicians should avoid routine combination therapy of vancomycin and rifampin for methicillin-resistant Staphylococcus aureus infections. This combination can lead to the development of stable rifampin resistance, compromising treatment efficacy.
Area of Science:
- Infectious Diseases
- Medical Microbiology
- Pharmacology
Background:
- Rising incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections.
- Vancomycin hydrochloride is the primary cell-wall antibiotic for MRSA.
- Combination antibiotic therapies are explored for enhanced MRSA treatment.
Observation:
- Rifampin is considered for its potent bactericidal activity against Staphylococcus aureus.
- Concurrent use of rifampin with cell-wall antibiotics was hypothesized to prevent rifampin resistance.
- A case of MRSA infection developed stable rifampin resistance during vancomycin and rifampin therapy.
Findings:
- Rifampin resistance emerged and persisted despite serial passages.
- The observed rifampin resistance was stable.
- This case challenges the assumption that combination therapy prevents rifampin resistance.
Implications:
- Caution is advised against the indiscriminate use of rifampin with vancomycin for MRSA.
- Routine combination therapy may inadvertently promote antibiotic resistance.
- Further research is needed to understand resistance mechanisms and optimize MRSA treatment strategies.